Exclusive: Negev Labs unveils with $30M in assets, striving to build a network of psychedelic biotechs

Max Bayer

Pharma Reporter

A new psychedelic-focused startup incubator is debuting, backed by an investor behind some of the most prominent biotechs in the space. The main theme of …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Exclusive: Negev Labs unveils with $30M in assets, striving to build a network of psychedelic biotechs

Max Bayer

Pharma Reporter

Sign up to read this article for free.

Director Oligonucleotide R&D

Bachem

Bubendorf, BL, Switzerland

Pfizer CEO says opportunities with Trump ‘clearly outweigh’ the risks for pharma

CBER's deputy director departs as staff shakeup continues

Bluebird bio to sell to investment funds after struggling to make money from gene therapies

FDA approves first drug to treat ultra-rare lipid storage disease

Eli Lilly stockpiles $548M of oral weight loss drug ahead of launch

Trusted protection: Why the current meningococcal vaccination schedule shouldn’t change without strong evidence

Ex­clu­sive: Negev Labs un­veils with $30M in as­sets, striv­ing to build a net­work of psy­che­del­ic biotechs

Pharma Reporter

Sign up to read this article for free.

Bachem

Bubendorf, BL, Switzerland

Exclusive: Negev Labs unveils with $30M in assets, striving to build a network of psychedelic biotechs